ATE385234T1 - Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren - Google Patents
Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitorenInfo
- Publication number
- ATE385234T1 ATE385234T1 AT04710346T AT04710346T ATE385234T1 AT E385234 T1 ATE385234 T1 AT E385234T1 AT 04710346 T AT04710346 T AT 04710346T AT 04710346 T AT04710346 T AT 04710346T AT E385234 T1 ATE385234 T1 AT E385234T1
- Authority
- AT
- Austria
- Prior art keywords
- xanthine derivatives
- sulfonamide substituted
- substituted xanthine
- pepck inhibitors
- pepck
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 title 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003456 sulfonamides Chemical group 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004110 gluconeogenesis Effects 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44856203P | 2003-02-19 | 2003-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE385234T1 true ATE385234T1 (de) | 2008-02-15 |
Family
ID=32908606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04710346T ATE385234T1 (de) | 2003-02-19 | 2004-02-12 | Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1599477B1 (de) |
| JP (1) | JP2006515337A (de) |
| KR (1) | KR100728425B1 (de) |
| CN (1) | CN100361992C (de) |
| AT (1) | ATE385234T1 (de) |
| AU (1) | AU2004213124A1 (de) |
| BR (1) | BRPI0407695A (de) |
| CA (1) | CA2514472A1 (de) |
| DE (1) | DE602004011603T2 (de) |
| ES (1) | ES2298722T3 (de) |
| MX (1) | MXPA05008672A (de) |
| PL (1) | PL378555A1 (de) |
| RU (1) | RU2340613C2 (de) |
| WO (1) | WO2004074288A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| GB0815947D0 (en) * | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| TWI598337B (zh) * | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TWI549947B (zh) * | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2019318209B2 (en) | 2018-08-10 | 2025-09-25 | Diapin Therapeutics, Llc | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE234099T1 (de) * | 1998-04-24 | 2003-03-15 | Leuven K U Res & Dev | Immununterdrückende effekte von 8 substituierten xanthinderivaten |
| GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2487033C (en) * | 2002-06-12 | 2009-08-11 | F. Hoffmann-La Roche Ag | Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
-
2004
- 2004-02-12 RU RU2005128833/04A patent/RU2340613C2/ru not_active IP Right Cessation
- 2004-02-12 KR KR1020057015234A patent/KR100728425B1/ko not_active Expired - Fee Related
- 2004-02-12 EP EP04710346A patent/EP1599477B1/de not_active Expired - Lifetime
- 2004-02-12 DE DE602004011603T patent/DE602004011603T2/de not_active Expired - Lifetime
- 2004-02-12 JP JP2006500028A patent/JP2006515337A/ja active Pending
- 2004-02-12 CA CA002514472A patent/CA2514472A1/en not_active Abandoned
- 2004-02-12 BR BRPI0407695-8A patent/BRPI0407695A/pt not_active IP Right Cessation
- 2004-02-12 AU AU2004213124A patent/AU2004213124A1/en not_active Abandoned
- 2004-02-12 WO PCT/EP2004/001289 patent/WO2004074288A1/en not_active Ceased
- 2004-02-12 ES ES04710346T patent/ES2298722T3/es not_active Expired - Lifetime
- 2004-02-12 MX MXPA05008672A patent/MXPA05008672A/es active IP Right Grant
- 2004-02-12 CN CNB2004800047229A patent/CN100361992C/zh not_active Expired - Fee Related
- 2004-02-12 AT AT04710346T patent/ATE385234T1/de not_active IP Right Cessation
- 2004-02-12 PL PL378555A patent/PL378555A1/pl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100728425B1 (ko) | 2007-06-13 |
| EP1599477A1 (de) | 2005-11-30 |
| AU2004213124A1 (en) | 2004-09-02 |
| EP1599477B1 (de) | 2008-01-30 |
| ES2298722T3 (es) | 2008-05-16 |
| RU2005128833A (ru) | 2006-07-27 |
| CA2514472A1 (en) | 2004-09-02 |
| JP2006515337A (ja) | 2006-05-25 |
| RU2340613C2 (ru) | 2008-12-10 |
| DE602004011603D1 (de) | 2008-03-20 |
| MXPA05008672A (es) | 2005-10-18 |
| BRPI0407695A (pt) | 2006-03-01 |
| DE602004011603T2 (de) | 2009-01-29 |
| CN100361992C (zh) | 2008-01-16 |
| KR20050107432A (ko) | 2005-11-11 |
| WO2004074288A1 (en) | 2004-09-02 |
| PL378555A1 (pl) | 2006-05-02 |
| CN1751044A (zh) | 2006-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE385234T1 (de) | Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren | |
| NO20070555L (no) | Kinazolinonderivater som parp-inhibitorer | |
| ATE377004T1 (de) | Proteinkinaseinhibitoren | |
| ATE457025T1 (de) | Kinaseinhibitoren | |
| DK1689715T3 (da) | Tubulininhibitorer | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| CY1110392T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| CY1113029T1 (el) | Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| EA200800873A1 (ru) | Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы | |
| EA200700185A1 (ru) | Производные хиназолиндиона в качестве ингибиторов parp | |
| DE69912581D1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| EP1616866A4 (de) | M-stage-kinesin-inhibitor | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| ATE413882T1 (de) | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren | |
| MXPA05009282A (es) | Derivados de anilina sustituidos. | |
| ATE399168T1 (de) | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren | |
| EP1671957A4 (de) | Thiadiazolinderivate | |
| ATE364384T1 (de) | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren | |
| EA200970497A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
| ATE486878T1 (de) | Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin | |
| NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer | |
| CA2487033A1 (en) | Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1599477 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |